Next Article in Journal
Induction of Mitochondrial Dependent Apoptosis in Human Leukemia K562 Cells by Meconopsis integrifolia: A Species from Traditional Tibetan Medicine
Next Article in Special Issue
RNA Aptamers as Molecular Tools to Study the Functionality of the Hepatitis C Virus CRE Region
Previous Article in Journal
Chemical Characterization of Different Sumac and Pomegranate Extracts Effective against Botrytis cinerea Rots
Previous Article in Special Issue
Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics
Article Menu

Export Article

Open AccessReview
Molecules 2015, 20(7), 11959-11980;

A Highlight of Recent Advances in Aptamer Technology and Its Application

Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX 77030, USA
Author to whom correspondence should be addressed.
Academic Editors: Alain O.A. Miller and Jean Jacques Vanden Eynde
Received: 8 June 2015 / Revised: 23 June 2015 / Accepted: 25 June 2015 / Published: 30 June 2015
(This article belongs to the Special Issue Aptamers: Past, Present, and Future)
Full-Text   |   PDF [1254 KB, uploaded 30 June 2015]   |  


Aptamers and SELEX (systematic evolution of ligands by exponential enrichment) technology have gained increasing attention over the past 25 years. Despite their functional similarity to protein antibodies, oligonucleotide aptamers have many unique properties that are suitable for clinical applications and industrialization. Aptamers may be superior to antibodies in fields such as biomarker discovery, in vitro and in vivo diagnosis, precisely controlled drug release, and targeted therapy. However, aptamer commercialization has not occurred as quickly as expected, and few aptamer-based products have yet successfully entered clinical and industrial use. Thus, it is important to critically review some technical barriers of aptamer and SELEX technology per se that may impede aptamer development and application. To date, how to rapidly obtain aptamers with superior bioavailability over antibodies remains the key issue. In this review, we discuss different chemical and structural modification strategies aimed to enhance aptamer bioavailability. We also discuss improvements to SELEX process steps to shorten the selection period and improve the SELEX process success rate. Applications in which aptamers are particularly suited and perform differently or superior to antibodies are briefly introduced. View Full-Text
Keywords: aptamer; SELEX; modification; optimization; improvement; application aptamer; SELEX; modification; optimization; improvement; application

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Sun, H.; Zu, Y. A Highlight of Recent Advances in Aptamer Technology and Its Application. Molecules 2015, 20, 11959-11980.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top